Lomond Therapeutics Holdings, Inc. financial data

Location
C/O Lomond Therapeutics Holdings, Inc., 8 The Green Ste 8490, Dover, DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 65.7 %
Debt-to-equity 30.9 %
Return On Equity -45.6 %
Return On Assets -34.9 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32.2M shares +544%
Common Stock, Shares, Outstanding 32.2M shares +544%
Entity Public Float 0 USD
Common Stock, Value, Issued 4.72K USD +844%
Weighted Average Number of Shares Outstanding, Basic 32.2M shares +4142%
Weighted Average Number of Shares Outstanding, Diluted 32.2M shares +4142%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.62M USD +120%
General and Administrative Expense 4.1M USD +1624%
Operating Income (Loss) -10.9M USD -146%
Nonoperating Income (Expense) 300K USD
Net Income (Loss) Attributable to Parent -10.3M USD -136%
Earnings Per Share, Basic 0 USD/shares +94.4%
Earnings Per Share, Diluted 0 USD/shares +94.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.65M USD
Assets, Current 2.27K USD +13.7%
Assets 2.27K USD +13.7%
Accounts Payable, Current 5.79M USD
Accrued Liabilities, Current 100K USD
Liabilities, Current 6.49M USD +4960%
Liabilities 9.53M USD +7334%
Retained Earnings (Accumulated Deficit) -45M USD -39385%
Stockholders' Equity Attributable to Parent 30M USD
Liabilities and Equity 2.27K USD +13.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -705K USD -437%
Net Cash Provided by (Used in) Financing Activities 15K USD -13.7%
Net Cash Provided by (Used in) Investing Activities -10.1M USD
Common Stock, Shares Authorized 300M shares +500%
Common Stock, Shares, Issued 32.2M shares +544%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.92K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.27K USD +13.7%
Deferred Tax Assets, Valuation Allowance 11.1M USD +65.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 11.1M USD +65.5%
Deferred Tax Assets, Operating Loss Carryforwards 3.36M USD +53.9%
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 86.5M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%